Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Clinical Trial Of L-Grb-2 Antisense Oligonucleotide In CML, AML, ALL & MDS" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Clinical Trial Of L-Grb-2 Antisense Oligonucleotide In CML, AML, ALL & MDS for you to read. Along with our medical data and news we also list Clinical Trial Of L-Grb-2 Antisense Oligonucleotide In CML, AML, ALL & MDS Clinical Trials, which are updated daily. BioPortfolio also has a large database of Clinical Trial Of L-Grb-2 Antisense Oligonucleotide In CML, AML, ALL & MDS Companies for you to search.
MUMBAI, India, Feb. 21, 2019/PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as "Cipla") and Wellthy Therapeutics Private Limited ("Wellthy Therapeutics") today announced that they have entered into a partnership to offer a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of Diabet...
PRESS RELEASE: REGULATED INFORMATION21 February 2019, 07:00 CET BioCARTIS to Host Webcast FOR ANNOUNCEMENT 2018 FINANCIAL Results on 28 FEBRUARY 2019 Mechelen, Belgium, 21 February 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company, today announces that it will host a live webcast on Thursday 28 Februar...
Valneva Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 2019 Major R&D milestones achieved in 2018, double-digit product sales revenue growth delivered; Lyme and chikungunya programs expected to advance further in 2019 Strong financial results in 2018 Product sales r
PureTech Health plc (LSE: PRTC) (“PureTech Health”), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis, today announced two presentations at upcoming investor conferences. Daphne Zohar, co-founder and chief executive officer, will present at the SVB Leerink Global Healthcare Conf...
Today's Daily Dose brings you news about Achieve Life Sciences' progress in ORCA-1 trial; Agios Pharma's near-term regulatory catalyst; new development related to ARCA biopharma's PRECISION-AF pivotal study; financial outlook of Genomic Health and NuVasive; near-term clinical trial catalyst of Sarepta; and partial clinical hold on Xencor's phase I acute myeloid leukemia trial.
Primary care physicians (PCPs) need to become more active participants in treating the Top 10 medical conditions with significant practice variations. “Nationally, PCPs are solely involved in treating less than 25% of medical condition episodes with the most practice variations,” stated Dr. Douglas G. Cave, President of
Gordon will expand the scientific research surrounding vestibular audiology to continue to improve the development and implementation of the most clinically advanced approaches to diagnosing and treating vestibular dysfunction. Gordon’s research will advance the use of the Institute’s proprietary Advanced Vestibular Treatment™ (AVT) in treating patients with dizziness, vertigo and balance di...
First-in-class antibody targeting B7-H4 Dual mechanism blocks a T cell checkpoint pathway and delivers potent antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that express B7-H4 B7-H4 is over-expressed on hard-to-treat solid tumors with low response to checkpoint inhibition ...
Blaze Bioscience, a Seattle-based biotech developing “tumor paint” that could help surgeons tell the difference between normal and cancerous tissue, has raised $5 million in new equity funding to help advance its lead product candidate through clinical trials. Heather Franklin, Blaze’s founder and CEO, says its latest funding round is still open, and could climb […]
Targeting DDR2 enhances tumor response to anti–PD-1 #immunotherapy https://medicalxpress.com/news/2019-02-potentially-immunotherapy-cancer.html … http://advances.sciencemag.org/content/5/2/eaav2437 … Maybe $BMY had a working I/O combo under its
Targeting DDR2 enhances tumor response to anti–PD-1 #immunotherapy https://medicalxpress.com/news/2019-02-potentially-immunotherapy-cancer.html … http://advances.sciencemag.org/content/5/2/eaav2437 … Maybe $BMY had a working I/O combo under its nose all along? Looking fwd to Nivolumab + Dasatinib combo data from this trial https://clinicaltrials.gov/ct2/show...
Our @Aiims1742 shares insights on the current treatment landscape of #pancreaticcancer and what's ahead with clinical trials: http://bit.ly/2NnCT0R @cure_magazine #pancsm #endcancer
In pharmaceutical companies, rats are used commonly in nonclinical studies to investigate the safety, efficacy, and pharmacokinetic profiles of drug candidates before they are entered into clinical studies. Most compounds administered via the oral route are metabolized in the liver and intestine, so the metabolism is a key determinant of pharmacokinetics.
A new "smart drug" has shown promise for women with metastatic triple-negative breast cancer, based on data from a clinical trial published in the New England Journal of Medicine. "I think this drug has the potential to change practice, because the...
The first clinical study investigating the use of the direct oral anticoagulant, rivaroxaban, to prevent blood clots in patients with cancer at high-risk published today in the New England Journal of Medicine. The study found no significant reduction in...
Minimally Invasive UroLift System Treatment Provides Rapid Symptom Relief and Improved Quality of Life, While Preserving Sexual Function*1,2 Teleflex Incorporated (NYSE:TFX) today announced that 100,000 patients have been treated globally with its minimally invasive UroLift® System, a safe and effective treatment for men with Benign Prostatic Hyperpla...
“We are working with the investigators and the @US_FDA and will provide an update when more information about resuming enrollment can be shared,” Xencor ($XNCR) President and CEO @BDahiyat says re: clinical hold on XmAb14045 trial: http://ow.ly/amrW30
“We are working with the investigators and the @US_FDA and will provide an update when more information about resuming enrollment can be shared,” Xencor ($XNCR) President and CEO @BDahiyat says re: clinical hold on XmAb14045 trial: http://ow.ly/amrW30nLLpS
Veracyte, Inc. (Nasdaq: VCYT) today announced that members of its management team will be participating in two upcoming investor conferences. Executives from the company will be meeting with investors at the BTIG MedTech, Life Science & Diagnostic Tools Conference 2019 on Wednesday, February 27, 2019, in Snowbird, Utah. There will not be a webcasted ...
HID Global®, a worldwide leader in trusted identity solutions, today announced that its IdenTrust® Enterprise Solution has been certified compliant with SAFE-BioPharma Association’s digital identity and signature standards, paving the way for the association’s global member companies to confidently deploy the solution. SAFE-BioPharma Association was ...
HCA Healthcare veteran Terence van Arkel named North Carolina Division CFO; Mission Health’s Ron Paulus to remain with HCA HCA Healthcare (NYSE: HCA), a leading healthcare provider with 185 hospitals and more than 1,800 sites of care in 21 states and the United Kingdom, today announced veteran hospital leader Greg Lowe has been named president of the...
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, applauds the U.S. Food & Drug Administration (FDA) approval of Merck’s pembrolizumab (Keytruda®) in the adjuvant setting for melanoma patients with lymph node involvement following complete lymph node resection. Melanoma, the deadliest skin c...
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference in NYC on February 27, 2019 at 2:30pm ET. The presentation will be webcast live and can be accessed via the investor section...
The combination of pembrolizumab plus best supportive care for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy did not improve progression-free or overall survival compared with placebo plus best supportive care alone, missing the coprimary endpoints of the KEYNOTE-240 trial.
Raleigh Neurology Associates, P.A., one of the largest and most respected neurology practices in the nation announces that Mark Ragusa has joined the practice as Director of Clinical Research at its main office in Raleigh, NC. Mark is an accomplished leader in the healthcare entrepreneurial technology industry. As Director of Clinical Research, Ma...
BLOOMINGTON, Ind.–(BUSINESS WIRE)–A recently published multi-center, randomized, controlled trial (RCT) demonstrated higher rates of healing when using OASIS® Wound Matrix with standard of care (SOC) for the treatment of full-thickness Stage III or Stage IV pressure ulcers than when using … Continue reading →
The company said it had shared data from the Phase III study with the FDA. However, per FDA regulations, there is a risk that the accele